What happened with INDV today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Indivior Pharmaceuticals, Inc. supplies medicines for people with opioid use disorder. Its main product, SUBLOCADE, delivers buprenorphine through a monthly injection administered by a healthcare professional. It also sells SUBOXONE Film, which dissolves under the tongue, and tablets in some markets outside the United States. Most revenue comes from the United States, where its commercial efforts focus on SUBLOCADE; its film and tablet businesses face substantial competition and declining sales.
The company sells to pharmaceutical wholesalers, specialty pharmacies and distributors that supply the treatment system. Medicaid and commercial insurers cover most of its products, making reimbursement important to patient access and sales. Its three largest customers are U.S. wholesalers, primarily buying SUBOXONE Film, and together account for a large share of revenue. SUBLOCADE reaches healthcare providers through specialty pharmacies and distributors: U.S. safety rules prohibit dispensing it directly to patients. Settlement terms also restrict Indivior’s U.S. promotion of SUBOXONE Film.
Product supply depends on outside manufacturers as well as ingredients supplied by Indivior. Curia manufactures SUBLOCADE, while Aquestive Therapeutics is the exclusive global manufacturer and primary packager of SUBOXONE Film. These relationships underpin the supply of its principal medicines.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Indivior’s results increasingly hinge on SUBLOCADE adoption and competition from Camurus’s long-acting buprenorphine treatment, sold by Braeburn as BRIXADI in the United States and as BUVIDAL elsewhere.
Alkermes Inc. plc competes for opioid-dependence treatment sales with VIVITROL against Indivior’s SUBLOCADE injection and buprenorphine medicines taken under the tongue. Watch VIVITROL’s performance in opioid dependence for a read on competition facing SUBLOCADE, which supplied 69% of Indivior’s 2025 net revenue.
Indivior depends on Aquestive Therapeutics, Inc. to manufacture and perform primary packaging for all SUBOXONE Film worldwide, supplying Aquestive with the active ingredients itself. Aquestive earns revenue from making licensed medicines, so news about its SUBOXONE Film production directly matters to the supply of Indivior’s opioid-dependence treatment.
Dr. Reddy’s Laboratories sells generic buprenorphine/naloxone film directly against Indivior’s SUBOXONE Film, contributing to the branded medicine’s loss of sales to generics. Its competing film is the product to watch for pressure on Indivior’s SUBOXONE business.
Dr. Reddy's Laboratories Limited earningsRDY
Dr. Reddy’s report will show whether its generic buprenorphine/naloxone film is continuing to take sales from Indivior’s SUBOXONE Film.
Look for Dr. Reddy’s sales or demand commentary on its generic film. Stronger sales would signal continued competitive pressure on SUBOXONE Film and make it harder for Indivior to hold its sublingual business; weaker sales would suggest that pressure may be easing, but would not prove Indivior’s own sales have recovered.
Alkermes Inc. plc earningsALKS
Alkermes’ report will show demand for VIVITROL in opioid-dependence treatment, a read on competition for Indivior’s SUBLOCADE and buprenorphine medicines.
Watch Alkermes’ commentary on VIVITROL sales or demand. Stronger demand would suggest VIVITROL is gaining in opioid-dependence treatment and intensifying competition for SUBLOCADE and other buprenorphine medicines; weaker demand would ease that competitive signal, but would not by itself show how Indivior’s products are performing.
Indivior Pharmaceuticals, Inc. earningsThis company
Indivior’s report will show whether SUBLOCADE’s growth can offset declining sales of its under-the-tongue medicines and support operating income.
Compare SUBLOCADE sales with sales of sublingual medicines, then check whether operating income holds up. SUBLOCADE growth alongside slower sublingual declines and steady operating income would show the newer product is replacing revenue from older products; slowing SUBLOCADE sales, continued sublingual declines, or weaker operating income would show the transition is not keeping pace and profits are under pressure.
Aquestive Therapeutics, Inc. earningsAQST
Aquestive Therapeutics’ report may show whether its production and primary packaging of SUBOXONE Film for Indivior are steady, a link in the medicine’s supply.
Read Aquestive’s commentary on pharmaceutical manufacturing and packaging, looking for specific mention of SUBOXONE Film. Steady related operations would suggest this outsourced link in Indivior’s supply is holding; a production or packaging disruption tied to the film could constrain SUBOXONE Film availability. If Aquestive gives no product-specific detail, its overall results cannot establish the medicine’s supply status.
